This $819,841 federal Project Grant awarded by the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), supports Duke University's research to pharmacologically activate a newly discovered KEAP1-ATF4-CHOP axis in order to select against targeted therapy resistance in non-small cell lung cancer (NSCLC). The research project aims to develop new treatments that can overcome resistance to existing targeted therapies for NSCLC. Duke University, through its Office of Research Administration Division, will serve as the prime contractor for this 3-year research grant, with a performance period from June 1, 2024 to May 31, 2027.